DOI: 10.1055/s-00000030

Der Klinikarzt

References

Gianni L, Bisagni G, Colleoni M. et al.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.

Lancet Oncol 2018;
19: 249-256

Download Bibliographical Data

Search in:
Access:
Access: